Advertisement

Pharmacodynamic Interactions Between Antiretrovirals and Other Agents

  • Kyle John Wilby
  • Tony K. L. Kiang
  • Mary H. H. Ensom
Chapter

Abstract

This chapter will provide an overview of pharmacodynamic drug interactions associated with antiretroviral agents and commonly co-administered agents. By the end of this chapter, the reader will develop an understanding of pharmacodynamic interactions and how they may positively or negatively impact care.

Keywords

Mycophenolate Mofetil Combination Index Nucleoside Reverse Transcriptase Inhibitor Pharmacodynamic Interaction Antitubercular Agent 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Kulkarni R, Hluhanich R, McColl DM, Miller MD, White KL (2014) The combined anti-HIV-1 activities of emtricitabine and tenofovir plus the integrase inhibitor elvitegravir or raltegravir show high levels of synergy In Vitro. Antimicrob Agents Chemother 58(10):6145–6150CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Department of Health and Human Services. 2016. Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed 15 June 2016
  3. 3.
    Rosenkranz SL, Yarasheski KE, Para MF, Reichman RC, Morse GD (2007) Antiretroviral drug levels and interactions affect lipid, lipoprotein and glucose metabolism in HIV-1 seronegative subjects: a pharmacokinetic-pharmacodynamic analysis. Metab Syndr Relat Disord 5(2):163–173CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Skinner-Adams TS, Andrews KT, Melville L, McCarthy J, Gardiner DL (2007) Synergistic interactions of the antiretroviral protease inhibitors saquinavir and ritonavir with chloroquine and mefloquine against Plasmodium falciparum in vitro. Antimicrob Agents Chemother 51(2):759–762CrossRefPubMedGoogle Scholar
  5. 5.
    Li X, He Z, Chen L, Li Y, Li Q, Zhao S et al (2011) Synergy of the antiretroviral protease inhibitor indinavir and chloroquine against malaria parasites in vitro and in vivo. Parasitol Res 109(6):1519–1524CrossRefPubMedGoogle Scholar
  6. 6.
    Khoo SH, Gibbons S, Seden K, Back DJ. Drug-drug interactions between antiretrovirals and medications used to treat TB, malaria, hepatitis B&C and opioid dependence. Last updated 2009. Available from: http://www.who.int/hiv/topics/treatment/drug_drug_interactions_review.pdf. Accessed 25 May 2016
  7. 7.
    Suthar AB, Lawn SD, del Amo J, Getahun H, Dye C, Sculier D et al (2012) Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis. PLoS Med 9(7):e1001270CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Podany AT, Bao Y, Swindells S, Chaisson RE, Andersen JW, Mwelase T et al (2015) Efavirenz pharmacokinetics and pharmacodynamics in HIV-infected persons receiving rifapentine and isoniazid for tuberculosis prevention. Clin Infect Dis 61(8):1322–1327CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Semvua HH, Kibiki GS, Kisanga ER, Boeree MJ, Burger DM, Aarnoutse R (2015) Pharmacological interactions between rifampicin and antiretroviral drugs: challenges and research priorities for resource-limited settings. Ther Drug Monit 37(1):22–32CrossRefPubMedGoogle Scholar
  10. 10.
    Antoniou T, Tseng AL (2005) Interactions between antiretrovirals and antineoplastic drug therapy. Clin Pharmacokinet 44(2):111–145CrossRefPubMedGoogle Scholar
  11. 11.
    Toffoli G, Corona G, Cattarossi G, Boiocchi M, Di Gennaro G, Tirelli U et al (2004) Effect of highly active antiretroviral therapy (HAART) on pharmacokinetics and pharmacodynamics of doxorubicin in patients with HIV-associated non-Hodgkin’s lymphoma. Ann Oncol 15(12):1805–1809CrossRefPubMedGoogle Scholar
  12. 12.
    McCance-Katz EF, Gruber VA, Beatty G, Lum PJ, Rainey PM (2013) Interactions between alcohol and the antiretroviral medications ritonavir or efavirenz. J Addict Med 7(4):264–270CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Kharasch ED, Whittington D, Ensign D, Hoffer C, Bedynek PS, Campbell S et al (2012) Mechanism of efavirenz influence on methadone pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 91(4):673–684CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Douglas Bruce R, Winkle P, Custodio JM, Wei X, Rhee MS, Kearney BP et al (2013) Investigation of the interactions between methadone and elvitegravir-cobicistat in subjects receiving chronic methadone maintenance. Antimicrob Agents Chemother 57(12):6154–6157CrossRefPubMedGoogle Scholar
  15. 15.
    McCance-Katz EF, Rainey PM, Smith P, Morse GD, Friedland G, Boyarsky B et al (2006) Drug interactions between opioids and antiretroviral medications: interaction between methadone, LAAM, and delavirdine. Am J Addict 15(1):23–34CrossRefPubMedGoogle Scholar
  16. 16.
    Bani-Sadr F, Denoeud L, Morand P, Lunel-Fabiani F, Pol S, Cacoub P et al (2007) Early virologic failure in HIV coinfected hepatitis C patients treated with the peginterferon-ribavirin combination does abacavir play a role? J Acquir Immune Defic Syndr 45(1):123–125CrossRefPubMedGoogle Scholar
  17. 17.
    Mira J, Lopez-Cortez L, Merino D, Arizcorreta-Yarza A, Rivero A, Collado A et al (2007) Predictors of severe hematological toxicity secondary to pegylated interferon plus ribavirin treatment in HIV-HCV coinfected patients. Antivir Ther 12(8):1225–1235PubMedGoogle Scholar
  18. 18.
    Wilby KJ, Greanya ED, Ford JE, Yoshida EM, Partovi N (2012) A review of drug interactions with boceprevir and telaprevir: implications for HIV and transplant patients. Ann Hepatol 11(2):179–185PubMedGoogle Scholar
  19. 19.
    Burgess S, Partovi N, Yoshida EM, Erb SR, Marquez Azalgara V, Hussaini T (2015) Drug interactions with direct-acting antivirals for hepatitis C: implications for HIV and transplant patients. Ann Pharmacother 49(6):674–687CrossRefPubMedGoogle Scholar
  20. 20.
    Millan O, Brunet M, Martorell J, García F, Vidal E, Rojo I et al (2005) Pharmacokinetics and pharmacodynamics of low dose mycophenolate mofetil in HIV-infected patients treated with abacavir, efavirenz and nelfinavir. Clin Pharmacokinet 44(5):525–538CrossRefPubMedGoogle Scholar
  21. 21.
    Brilhante RSN, Caetano EP, Riello GB, Guedes GM, Castelo-Branco Dde S et al (2016) Antriretroviral drugs saquinavir and ritonavir reduce inhibitory concentration values of itraconazole against Histoplasma capsulatum strains in vitro. Braz J Infect Dis 20(2):155–159CrossRefPubMedGoogle Scholar
  22. 22.
    Mastan SK, Eswar Kumar K (2009) Influence of non-nucleoside reverse transcriptase inhibitors (efavirenz and nevirapine) on the pharmacodynamic activity of gliclazide in animal models. Diabetol Metab Syndr 1(1):15. doi: 10.1186/1758-5996-1-15 CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Mastan SK, Eswar Kumar K (2010) Effect of antiretroviral drugs on the pharmacodynamics of gliclazide with respect to glucose-insulin homeostasis in animal models. J Exp Pharmacol 2:1–11PubMedGoogle Scholar
  24. 24.
    DeSilva KE, Le Flore DB, Marston BJ, Rimland D (2001) Serotonin syndrome in HIV-infected individuals receiving antiretroviral therapy and fluoxetine. AIDS 15:1281–1285CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media Singapore 2016

Authors and Affiliations

  • Kyle John Wilby
    • 1
  • Tony K. L. Kiang
    • 2
  • Mary H. H. Ensom
    • 2
  1. 1.College of PharmacyQatar UniversityDohaQatar
  2. 2.Faculty of Pharmaceutical SciencesThe University of British ColumbiaVancouverCanada

Personalised recommendations